SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 263 filers reported holding SAGE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 2.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $90,108,851 | -16.6% | 4,378,467 | +90.4% | 0.01% | -16.7% |
Q2 2023 | $108,105,563 | -5.8% | 2,299,140 | -15.9% | 0.01% | 0.0% |
Q1 2023 | $114,734,230 | -44.8% | 2,734,373 | -49.9% | 0.01% | 0.0% |
Q4 2022 | $208,038,138 | +79.8% | 5,454,592 | +84.6% | 0.01% | -14.3% |
Q3 2022 | $115,705,000 | +22.1% | 2,954,683 | +0.7% | 0.01% | +16.7% |
Q2 2022 | $94,770,000 | +1.0% | 2,934,064 | +3.5% | 0.01% | +20.0% |
Q1 2022 | $93,850,000 | +1.7% | 2,835,356 | +30.8% | 0.01% | +25.0% |
Q4 2021 | $92,249,000 | +5.4% | 2,168,530 | +9.7% | 0.00% | -20.0% |
Q3 2021 | $87,554,000 | +15.3% | 1,975,952 | +47.8% | 0.01% | +25.0% |
Q2 2021 | $75,941,000 | -19.3% | 1,336,758 | +6.3% | 0.00% | -20.0% |
Q1 2021 | $94,116,000 | -29.0% | 1,257,390 | -18.0% | 0.01% | -37.5% |
Q4 2020 | $132,609,000 | +45.8% | 1,532,879 | +3.0% | 0.01% | +33.3% |
Q3 2020 | $90,971,000 | +3.3% | 1,488,399 | -29.7% | 0.01% | 0.0% |
Q2 2020 | $88,039,000 | +81.9% | 2,117,336 | +25.6% | 0.01% | +50.0% |
Q1 2020 | $48,397,000 | -59.6% | 1,685,134 | +1.6% | 0.00% | -50.0% |
Q4 2019 | $119,682,000 | -17.9% | 1,657,872 | +59.5% | 0.01% | -27.3% |
Q3 2019 | $145,845,000 | -16.6% | 1,039,599 | +8.8% | 0.01% | -15.4% |
Q2 2019 | $174,935,000 | +5.1% | 955,461 | -8.7% | 0.01% | 0.0% |
Q1 2019 | $166,437,000 | +63.8% | 1,046,444 | -1.4% | 0.01% | +44.4% |
Q4 2018 | $101,617,000 | -28.5% | 1,060,834 | +5.5% | 0.01% | -18.2% |
Q3 2018 | $142,035,000 | -9.0% | 1,005,545 | +0.8% | 0.01% | -15.4% |
Q2 2018 | $156,128,000 | -21.4% | 997,406 | -19.1% | 0.01% | -23.5% |
Q1 2018 | $198,626,000 | +7.3% | 1,233,178 | +9.7% | 0.02% | +13.3% |
Q4 2017 | $185,084,000 | +139.0% | 1,123,672 | -9.6% | 0.02% | +114.3% |
Q3 2017 | $77,427,000 | -19.8% | 1,242,765 | +2.5% | 0.01% | -22.2% |
Q2 2017 | $96,558,000 | +20.7% | 1,212,384 | +7.7% | 0.01% | +28.6% |
Q1 2017 | $79,976,000 | +35.3% | 1,125,287 | -2.8% | 0.01% | +16.7% |
Q4 2016 | $59,107,000 | +9.7% | 1,157,665 | -1.1% | 0.01% | +20.0% |
Q3 2016 | $53,904,000 | +92.5% | 1,170,501 | +25.9% | 0.01% | +66.7% |
Q2 2016 | $28,002,000 | +20.5% | 929,473 | +28.2% | 0.00% | 0.0% |
Q1 2016 | $23,245,000 | -25.0% | 724,957 | +36.3% | 0.00% | 0.0% |
Q4 2015 | $31,011,000 | +17.3% | 531,935 | -14.9% | 0.00% | 0.0% |
Q3 2015 | $26,438,000 | -24.8% | 624,724 | +29.7% | 0.00% | -25.0% |
Q2 2015 | $35,177,000 | +835.3% | 481,815 | +542.9% | 0.00% | – |
Q1 2015 | $3,761,000 | +41.0% | 74,944 | +2.8% | 0.00% | – |
Q4 2014 | $2,668,000 | +76.1% | 72,872 | +51.5% | 0.00% | – |
Q3 2014 | $1,515,000 | – | 48,100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
RA Capital Management | 455,173 | $74,972,000 | 6.27% |
Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |